Literature DB >> 28267394

Downregulation of miR-377 Promotes Oral Squamous Cell Carcinoma Growth and Migration by Targeting HDAC9.

Bhawna Rastogi1, Amit Kumar2, Satish K Raut2, Naresh K Panda1, Vidya Rattan3, Nainesh Joshi2, Madhu Khullar2.   

Abstract

microRNAs are the post-transcriptional regulators implicated in the initiation and progression of various cancer types, including oral squamous cell carcinoma (OSCC). Here, we investigated the role of miR-377 in OSCC tumorigenesis. miR-377 expression was reduced in OSCC samples and cell line (UPCI-SCC-116), and was associated with patient survival. In vitro restoration of miR-377 repressed cell growth, induced apoptosis, and reduced cell migration. We identified HDAC9 as a target of miR-377 and found miR-377 to regulate HDAC9 and its pro-apoptotic target, NR4A1/Nur77. Our findings show that miR-377 targets HDAC9 pathway in OSCC, suggesting that miR-377-HDAC9 axis may provide a novel therapeutic target for OSCC therapy.

Entities:  

Keywords:  Histone deacetylase 9; Oral squamous cell carcinoma; microRNA-377

Mesh:

Substances:

Year:  2017        PMID: 28267394     DOI: 10.1080/07357907.2017.1286669

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  15 in total

1.  ST8SIA6-AS1 promotes hepatocellular carcinoma by absorbing miR-5195-3p to regulate HOXB6.

Authors:  Yang Li; An Jiang
Journal:  Cancer Biol Ther       Date:  2020-05-18       Impact factor: 4.742

2.  MicroRNA-377-3p inhibits growth and invasion through sponging JAG1 in ovarian cancer.

Authors:  Liulin Tang; Bin Yang; Xiaolan Cao; Qin Li; Li Jiang; Dan Wang
Journal:  Genes Genomics       Date:  2019-04-30       Impact factor: 1.839

3.  Long non-coding RNA BBOX1-antisense RNA 1 enhances cell proliferation and migration and suppresses apoptosis in oral squamous cell carcinoma via the miR-3940-3p/laminin subunit gamma 2 axis.

Authors:  Chunguang Zhao; Wei Shi; Min Chen
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

4.  TCGA based integrated genomic analyses of ceRNA network and novel subtypes revealing potential biomarkers for the prognosis and target therapy of tongue squamous cell carcinoma.

Authors:  Zaiye Li; Canhua Jiang; Yongxiang Yuan
Journal:  PLoS One       Date:  2019-05-29       Impact factor: 3.240

5.  STAT3-induced upregulation of lncRNA MEG3 regulates the growth of cardiac hypertrophy through miR-361-5p/HDAC9 axis.

Authors:  Jingchang Zhang; Yi Liang; Xuecheng Huang; Xiaoyan Guo; Yang Liu; Jiming Zhong; Jielin Yuan
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

6.  Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment.

Authors:  Zhi-Xuan Li; Zi-Qi Zheng; Zhuo-Hui Wei; Lu-Lu Zhang; Feng Li; Li Lin; Rui-Qi Liu; Xiao-Dan Huang; Jia-Wei Lv; Fo-Ping Chen; Xiao-Jun He; Jia-Li Guan; Jia Kou; Jun Ma; Guan-Qun Zhou; Ying Sun
Journal:  Theranostics       Date:  2019-10-14       Impact factor: 11.556

Review 7.  Prospective applications of microRNAs in oral cancer.

Authors:  Chuan Fang; Yadong Li
Journal:  Oncol Lett       Date:  2019-08-16       Impact factor: 2.967

8.  TRIB3 promotes oral squamous cell carcinoma cell proliferation by activating the AKT signaling pathway.

Authors:  Peng Shen; Tian-Yang Zhang; Shu-Yan Wang
Journal:  Exp Ther Med       Date:  2021-02-01       Impact factor: 2.447

9.  Expression and prognostic analyses of HDACs in human gastric cancer based on bioinformatic analysis.

Authors:  Luting Chen; Yuchang Fei; Yurong Zhao; Quan Chen; Peifeng Chen; Lei Pan
Journal:  Medicine (Baltimore)       Date:  2021-07-09       Impact factor: 1.817

10.  Mechanism of piR-DQ590027/MIR17HG regulating the permeability of glioma conditioned normal BBB.

Authors:  Xue Leng; Jun Ma; Yunhui Liu; Shuyuan Shen; Hai Yu; Jian Zheng; Xiaobai Liu; Libo Liu; Jiajia Chen; Lini Zhao; Xuelei Ruan; Yixue Xue
Journal:  J Exp Clin Cancer Res       Date:  2018-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.